citalopram/fluoxetine

1
Reactions 899 - 27 Apr 2002 S Citalopram/fluoxetine Serotonin syndrome presenting as coma: case report A 35-year-old woman became comatose due to serotonin syndrome during treatment with fluoxetine, and then again during treatment with citalopram. The woman, who was also receiving guaifenesin/ pseudoephedrine, received fluoxetine 20 mg/day after presenting with symptoms of anxiety and insomnia. She subsequently reported mild tremors. Approximately 2 months after starting fluoxetine, she became restless and then collapsed after consuming ‘a few’ alcoholic beverages. She was flaccid and unresponsive, and she then became apnoeic. Resuscitative efforts for approximately 1 hour restored spontaneous respiration, but she remained comatose for a further hour. She was observed until the morning and then discharged. Following the episode, the woman experienced diffuse aching of her muscles. Fluoxetine was withheld for 1 week after the event, and then restarted. She stopped all alcohol intake. Approximately 3 weeks later, she felt nauseous, and that evening was found in an unresponsive state. 30 minutes later, she became apnoeic. She was ventilated for 2 hours before she resumed spontaneous respiration. She received oxygen and IV dextrose overnight, but remained comatose until the following evening. Fluoxetine was stopped. She experienced diffuse muscular pain and weakness after the event, which was alleviated with magnesium and pyridoxine [vitamin B6] over the next 2 months. About 14 months later, the woman received gabapentin for insomnia, but this agent was temporally associated with the development of severe abdominal symptoms and was discontinued. Ten months later, she started citalopram 10 mg/day. Three days later, she experienced shakiness, tremulousness and palpitations after consuming 6 beer, and she became unresponsive and comatose. Neurological findings were identical to those evident during her episodes of fluoxetine-associated coma. Apnoea did not develop, and a step-wise recovery ensued after 3 hours. Her citalopram dosage was reduced to 5 mg/day. However, 3 days later, she experienced another episode of unresponsiveness and coma, without apnoea, lasting for 1.5 hours. Citalopram was stopped. She did not receive any further medications that increase serotonin activity and she had not experienced any further episodes of coma at follow-up approximately 10 months later. Author comment: ‘This case report demonstrates that when an SSRI [selective serotonin reuptake inhibitor] is the identified culprit in causing serotonin syndrome, it is best to avoid all SSRIs and possibly all serotonergic medications.’ Chechani V. Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Critical Care Medicine 30: 473-476, Feb 2002 - USA 800903068 1 Reactions 27 Apr 2002 No. 899 0114-9954/10/0899-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: vanhanh

Post on 16-Mar-2017

214 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Citalopram/fluoxetine

Reactions 899 - 27 Apr 2002

SCitalopram/fluoxetine

Serotonin syndrome presenting as coma: casereport

A 35-year-old woman became comatose due to serotoninsyndrome during treatment with fluoxetine, and then againduring treatment with citalopram.

The woman, who was also receiving guaifenesin/pseudoephedrine, received fluoxetine 20 mg/day afterpresenting with symptoms of anxiety and insomnia. Shesubsequently reported mild tremors. Approximately 2 monthsafter starting fluoxetine, she became restless and thencollapsed after consuming ‘a few’ alcoholic beverages. Shewas flaccid and unresponsive, and she then became apnoeic.Resuscitative efforts for approximately 1 hour restoredspontaneous respiration, but she remained comatose for afurther hour. She was observed until the morning and thendischarged.

Following the episode, the woman experienced diffuseaching of her muscles. Fluoxetine was withheld for 1 weekafter the event, and then restarted. She stopped all alcoholintake. Approximately 3 weeks later, she felt nauseous, andthat evening was found in an unresponsive state. 30 minuteslater, she became apnoeic. She was ventilated for 2 hoursbefore she resumed spontaneous respiration. She receivedoxygen and IV dextrose overnight, but remained comatoseuntil the following evening. Fluoxetine was stopped. Sheexperienced diffuse muscular pain and weakness after theevent, which was alleviated with magnesium and pyridoxine[vitamin B6] over the next 2 months.

About 14 months later, the woman received gabapentin forinsomnia, but this agent was temporally associated with thedevelopment of severe abdominal symptoms and wasdiscontinued. Ten months later, she started citalopram 10mg/day. Three days later, she experienced shakiness,tremulousness and palpitations after consuming 6 beer, andshe became unresponsive and comatose. Neurologicalfindings were identical to those evident during her episodes offluoxetine-associated coma. Apnoea did not develop, and astep-wise recovery ensued after 3 hours. Her citalopramdosage was reduced to 5 mg/day. However, 3 days later, sheexperienced another episode of unresponsiveness and coma,without apnoea, lasting for 1.5 hours. Citalopram wasstopped. She did not receive any further medications thatincrease serotonin activity and she had not experienced anyfurther episodes of coma at follow-up approximately 10months later.

Author comment: ‘This case report demonstrates that whenan SSRI [selective serotonin reuptake inhibitor] is the identifiedculprit in causing serotonin syndrome, it is best to avoid allSSRIs and possibly all serotonergic medications.’Chechani V. Serotonin syndrome presenting as hypotonic coma and apnea:potentially fatal complications of selective serotonin receptor inhibitor therapy.Critical Care Medicine 30: 473-476, Feb 2002 - USA 800903068

1

Reactions 27 Apr 2002 No. 8990114-9954/10/0899-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved